Share on StockTwits

Research analysts at Barclays increased their price objective on shares of Tornier NV (NASDAQ:TRNX) from $26.00 to $28.00 in a report released on Friday. Barclays’ price objective indicates a potential upside of 28.85% from the company’s current price.

Tornier NV (NASDAQ:TRNX) traded up 11.49% on Friday, hitting $21.73. 541,015 shares of the company’s stock traded hands. Tornier NV has a 1-year low of $15.17 and a 1-year high of $24.35. The stock has a 50-day moving average of $22.29 and a 200-day moving average of $20.51. The company’s market cap is $1.055 billion.

Tornier NV (NASDAQ:TRNX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by $0.04. The company had revenue of $86.85 million for the quarter, compared to the consensus estimate of $79.40 million. During the same quarter in the previous year, the company posted ($0.28) earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. Analysts expect that Tornier NV will post $-0.45 EPS for the current fiscal year.

TRNX has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets upgraded shares of Tornier NV from a “market perform” rating to an “outperform” rating in a research note on Friday. They now have a $24.00 price target on the stock, up previously from $20.00. Analysts at TheStreet upgraded shares of Tornier NV from a “sell” rating to a “hold” rating in a research note on Friday, June 6th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $22.67.

Tornier N.V. (NASDAQ:TRNX) is a global medical device company focused on surgeons that treat musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.